1. Home
  2. ARDX vs MNMD Comparison

ARDX vs MNMD Comparison

Compare ARDX & MNMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ARDX
  • MNMD
  • Stock Information
  • Founded
  • ARDX 2007
  • MNMD 2019
  • Country
  • ARDX United States
  • MNMD United States
  • Employees
  • ARDX N/A
  • MNMD N/A
  • Industry
  • ARDX Biotechnology: Pharmaceutical Preparations
  • MNMD Pharmaceuticals and Biotechnology
  • Sector
  • ARDX Health Care
  • MNMD Health Care
  • Exchange
  • ARDX Nasdaq
  • MNMD Nasdaq
  • Market Cap
  • ARDX 882.9M
  • MNMD 960.2M
  • IPO Year
  • ARDX 2014
  • MNMD N/A
  • Fundamental
  • Price
  • ARDX $5.04
  • MNMD $13.65
  • Analyst Decision
  • ARDX Strong Buy
  • MNMD Strong Buy
  • Analyst Count
  • ARDX 9
  • MNMD 7
  • Target Price
  • ARDX $10.50
  • MNMD $26.71
  • AVG Volume (30 Days)
  • ARDX 3.2M
  • MNMD 2.2M
  • Earning Date
  • ARDX 10-30-2025
  • MNMD 11-06-2025
  • Dividend Yield
  • ARDX N/A
  • MNMD N/A
  • EPS Growth
  • ARDX N/A
  • MNMD N/A
  • EPS
  • ARDX N/A
  • MNMD N/A
  • Revenue
  • ARDX $386,146,000.00
  • MNMD N/A
  • Revenue This Year
  • ARDX $17.34
  • MNMD N/A
  • Revenue Next Year
  • ARDX $27.08
  • MNMD N/A
  • P/E Ratio
  • ARDX N/A
  • MNMD N/A
  • Revenue Growth
  • ARDX 83.88
  • MNMD N/A
  • 52 Week Low
  • ARDX $3.21
  • MNMD $4.70
  • 52 Week High
  • ARDX $6.78
  • MNMD $13.86
  • Technical
  • Relative Strength Index (RSI)
  • ARDX 33.54
  • MNMD 66.18
  • Support Level
  • ARDX $4.71
  • MNMD $12.11
  • Resistance Level
  • ARDX $5.27
  • MNMD $13.09
  • Average True Range (ATR)
  • ARDX 0.19
  • MNMD 0.89
  • MACD
  • ARDX -0.04
  • MNMD 0.04
  • Stochastic Oscillator
  • ARDX 30.80
  • MNMD 90.07

About ARDX Ardelyx Inc.

Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. It product Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.

About MNMD Mind Medicine (MindMed) Inc.

Mind Medicine Inc. is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. It is developing a pipeline of product candidates targeting neurotransmitter pathways that play key roles in brain health disorders. This includes explicitly pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM120 and MM402, as its key product candidates. The MM120 is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that is being developed to treat generalized anxiety disorder and clinical depressive disorder, and the MM402 is a proprietary form of the R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA), being developed to treat autism spectrum disorder (ASD).

Share on Social Networks: